|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | April 10, 2001 | ||||
| Last Updated Date | June 23, 2005 | ||||
| Start Date ICMJE | January 2001 | ||||
| Primary Completion Date | |||||
| Current Primary Outcome Measures ICMJE | |||||
| Original Primary Outcome Measures ICMJE | |||||
| Change History | Complete list of historical versions of study NCT00014716 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | |||||
| Original Secondary Outcome Measures ICMJE | |||||
| Descriptive Information | |||||
| Brief Title ICMJE | Randomized Study of Ketorolac in Infants Undergoing Surgery | ||||
| Official Title ICMJE | |||||
| Brief Summary | OBJECTIVES: I. Determine the pharmacokinetics of ketorolac in infants following surgery. II. Determine the analgesic efficacy of this drug, in terms of infant pain score, time to first opiate medication, and total opioid administration, in these patients. III. Determine the toxicity of this drug in these patients. |
||||
| Detailed Description | PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (0-7 days vs 8-30 days vs 31-90 days vs 91-180 days vs 181-365 days vs 12-18 months). Patients are randomized to one of three treatment arms. Arm I: Patients receive low-dose ketorolac IV over 10 minutes on postoperative day 1 and morphine IV every 1-4 hours as needed. Treatment with ketorolac may continue every 8 hours for 2 days. Arm II: Patients receive high-dose ketorolac and morphine as in arm I. Arm III: Patients receive normal saline IV over 10 minutes on postoperative day 1 and morphine as in arm I. Patients in all arms are assessed for pain score every 2 hours for 4 hours prior to treatment and for 12 hours after treatment. |
||||
| Study Phase | |||||
| Study Type ICMJE | Interventional | ||||
| Study Design ICMJE | Treatment, Randomized, Double-Blind, Placebo Control | ||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Drug: ketorolac | ||||
| Study Arms / Comparison Groups | |||||
| Publications * | |||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Recruiting | ||||
| Enrollment ICMJE | 90 | ||||
| Completion Date | |||||
| Primary Completion Date | |||||
| Eligibility Criteria ICMJE | PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Full-term infants (at least 36 weeks gestation at birth) who are scheduled for one of the following surgeries requiring hospital admission postoperatively: exploratory laparotomy, pyloromyotomy, cleft lip repair, cleft palate repair, craniectomy, placement of ventriculo-peritoneal shunts, urologic surgery (with normal renal function), orthopedic procedures No post-operative analgesia managed with ongoing epidural infusions; single dose caudal epidural injections given intraoperatively allowed --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No concurrent gastrotonic agents such as reglan or cisapride; no concurrent coumadin or therapeutic heparin --Patient Characteristics-- Performance status: Not specified Hematopoietic: No patient or family history of bleeding or coagulation defects Hepatic: Hepatic function normal; no prior hepatic transplantation Renal: Renal function normal; no prior renal transplantation Other: No history of gastrointestinal bleeding; no closure of large gastroschisis or omphalocele defects (with increased intra-abdominal pressure); no prior repair of diaphragmatic hernia; no allergy to ketorolac |
||||
| Gender | Both | ||||
| Ages | up to 18 Months | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | |||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT ID ICMJE | NCT00014716 | ||||
| Responsible Party | |||||
| Study ID Numbers ICMJE | 199/15737, CHMC-S-FDR001815 | ||||
| Study Sponsor ICMJE | FDA Office of Orphan Products Development | ||||
| Collaborators ICMJE | Seattle Children's Hospital | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | FDA Office of Orphan Products Development | ||||
| Verification Date | May 2001 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||